首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.
【24h】

Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials.

机译:急性缺血性卒中的口服胞磷胆碱:临床试验的单个患者数据汇总分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: No single neuroprotective agent has been shown to influence outcome after acute stroke. Citicoline has been studied worldwide in many clinical trials with positive findings, but only 1 trial has obtained significant results in the primary efficacy variables. Our objective was to evaluate the effects of oral citicoline in patients with acute ischemic stroke by a data pooling analysis of clinical trials. The primary efficacy end point chosen was the common evaluation of recovery, combining National Institutes of Health Stroke Scale /=95 at 3 months using the generalized estimating equations analysis. METHODS: A systematic search of all prospective, randomized, placebo-controlled, double-blind clinical trials with oral citicoline (MEDLINE, Cochrane, and Ferrer Group bibliographic databases) was undertaken. Individual patient data were extracted from each study and pooled in a single data file. The main inclusion criteria included compatible neuroimaging with ischemic stroke, National Institutes of Health Stroke Scale >/=8, and prior modified Rankin Scale score
机译:背景与目的:尚未显示急性中风后单一神经保护剂会影响预后。在世界范围内已对Citicoline进行了许多临床试验研究,结果都是肯定的,但是只有1个试验在主要疗效变量上获得了显着结果。我们的目的是通过临床试验的数据汇总分析评估口服胞磷胆碱对急性缺血性中风患者的疗效。选择的主要疗效终点是对恢复的常规评估,并使用广义估计方程分析结合国立卫生研究院卒中量表 / = 95。 。方法:采用口服胞磷胆碱(MEDLINE,Cochrane和Ferrer Group书目数据库)对所有前瞻性,随机,安慰剂对照,双盲临床试验进行了系统搜索。从每个研究中提取单个患者数据,并将其合并到一个数据文件中。主要纳入标准包括与缺血性卒中相兼容的神经影像学,美国国立卫生研究院卒中量表> / = 8和先前修改的Rankin量表评分

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号